Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
Extending production capabilities to the Americas helps reduce labor costs and inventory complexity for nutraceuticals and other industries while maintaining superior moisture control
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Aims to boost speed & precision in patient care
The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances
_and_Dr__D_Nageshwar_Reddy_(AIG_Hospitals)_256_384.jpg)
The collaboration is designed to improve clinical outcomes, reduce procedural risks, and expand access to advanced image-guided treatments across a growing range of conditions
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
Subscribe To Our Newsletter & Stay Updated
